毒理性
◉ 母乳喂养期间使用总结：目前没有关于阿糖胞苷排入母乳的信息。然而，该药物在静脉给药后的半衰期短，为2到3小时，因此应在静脉给药后一天内从乳汁中消除。关于阿糖胞苷在哺乳期间使用的资料非常有限。在一例中，一位母亲在静脉接受阿糖胞苷、米托蒽醌和依托泊苷治疗3周后开始哺乳，对她婴儿没有明显伤害。在鞘内给药阿糖胞苷的脂质体配方后，血浆中的药物水平几乎检测不到，不太可能以临床相关量出现在乳汁中。
◉ 对哺乳婴儿的影响：一位母亲静脉接受了3天的米托蒽醌，每天剂量为6 mg/平方米，同时接受了5天的依托泊苷80 mg/平方米和阿糖胞苷170 mg/平方米。她在第三次米托蒽醌给药后3周恢复了哺乳，当时米托蒽醌在乳汁中仍可检测到。婴儿在16个月大时没有明显的异常。然而，在停止哺乳3周后，阿糖胞苷在哺乳期间存在于乳汁中的可能性不大。
◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。
◉ Summary of Use during Lactation:No information is available on the excretion of cytarabine into breastmilk. However, the drug has a short half-life of 2 to 3 hours after intravenous administration, so it should be eliminated from milk a day after intravenous administration. Very little information is available on the use of cytarabine during breastfeeding. In one case, a mother began breastfeeding her infant 3 weeks after receiving cytarabine, mitoxantrone and etoposide intravenously, with no apparent harm to her infant. After intrathecal administration of the liposomal formulation of cytarabine, drugs levels in plasma are barely detectable, and are unlikely to appear in milk in clinically relevant amounts.
◉ Effects in Breastfed Infants:One mother received 3 daily doses of 6 mg/sq. m. of mitoxantrone intravenously along with 5 daily doses of etoposide 80 mg/sq. m. and cytarabine 170 mg/sq. m. intravenously. She resumed breastfeeding her infant 3 weeks after the third dose of mitoxantrone at a time when mitoxantrone was still detectable in milk. The infant had no apparent abnormalities at 16 months of age. However, after 3 weeks of abstinence from breastfeeding, it is unlikely that cytarabine was present in milk during breastfeeding.
◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.
来源:Drugs and Lactation Database (LactMed)
